Skip to Content

WPI 2233 (Tamoxifen 20 mg)

Pill with imprint WPI 2233 is White, Round and has been identified as Tamoxifen citrate 20 mg. It is supplied by Watson Pharmaceuticals, Inc..

Tamoxifen is used in the treatment of breast cancer, metastatic; breast cancer; breast cancer, adjuvant; breast cancer, male; breast cancer, palliative (and more), and belongs to the drug classes hormones/antineoplastics, selective estrogen receptor modulators. There is positive evidence of human fetal risk during pregnancy. Tamoxifen 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2233

Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233 Front
Tamoxifen citrate 20 mg WPI 2233 Back
Tamoxifen citrate 20 mg WPI 2233

Tamoxifen citrate

WPI 2233
20 mg
Prescription only
Drug Class:
Selective estrogen receptor modulators
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Watson Pharmaceuticals, Inc.
Inactive Ingredients:
croscarmellose sodium
lactose monohydrate
magnesium stearate
microcrystalline cellulose
pregelatinized corn starch
Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2018, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.